Clinical and Laboratory Features of the Catastrophic Antiphospholipid Syndrome

详细信息    查看全文

• 作者：Ljudmila Stojanovich (1)
  Dragomir Marisavljevic (1)
  Jozef Rovensky (2)
  Aleksandra Djokovich (1)
  Darina Kozáková (2)
  Nikola Milinic (1)
  
• 关键词：Catastrophic (Asherson’s) syndrome ; Multi ; organ thrombosis ; Antiphospholipid antibodies
• 刊名：Clinical Reviews in Allergy & Immunology
• 出版年：2009
• 出版时间：June 2009
• 年：2009
• 卷：36
• 期：2-3
• 页码：74-79
• 全文大小：192KB
• 参考文献：1. Asherson RA (1992) The catastrophic antiphospholipid antibody syndrome. J Rheumatol 19:508-12
  2. Asherson RA, Cervera R, de Groot P et al (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530-34 CrossRef
  3. Asherson RA (2005) The Catastrophic Antiphospholipid (Asherson’s) Syndrome in 2004—a review. Autoimmun Rev 4:48-4 CrossRef
  4. Merrill JT, Asherson RA (2006) Catastrophic antiphospholipid syndrome. Nat Clin Pract Rheumatol 2:81-9 CrossRef
  5. Baryaktar UD, Erkan D, Bucciarelli S, Espinosa G, Aherson RA, for the Catastrohic Antiphospholipid Syndrome Project Group (2007) The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol 34:346-52
  6. Asherson RA, Cervera R, Piette JC et al (1998) Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine 77:195-07 CrossRef
  7. Tan DCL, Low AHL, Ong HS et al (2006) Unusual abdominal manifestations of catastrophic antiphospholipid syndrome. Br J Haematol 132(5):538-38 CrossRef
  8. Harris EN, Pierangeli SS (2008) Primary, secondary, and catastrophic antiphospholipid syndrome: what’s in a name? Semin Thromb Hemost 34(3):219-26 CrossRef
  9. Asherson RA, Cervera R, Piette JC, Shoenfeld Y et al (2001) Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine 80:355-77 CrossRef
  10. Kitchens CS (1998) Thrombotic storm: when thrombosis begets thrombosis. Am J Med 104:381-85 CrossRef
  11. Piette JC, Cervera R, Levy R et al (2003) The catastrophic antiphospholipid syndrome—Asherson’s syndrome. Ann Med Intern 154:95-6
  12. Cervera R, Bucciarelli S, Espinosa G et al (2007) Catastrophic antiphospholipid syndrome: lessons from the “CAPS Registry”—a tribute to the late Josep Font. Ann N Y Acad Sci 1108:448-56 CrossRef
  13. Asherson RA (2005) Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson’s) syndrome. Immunobiology 210:727-33 CrossRef
  14. Shoenfeld Y, Meroni PL, Cervera R (2008) Antiphospholipid syndrome dilemmas still to be solved: 2008 status. Ann Rheum Dis 67:438-42 CrossRef
  15. Shoenfeld Y, Blank M, Cervera R et al (2006) Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 65:2- CrossRef
  16. Asherson RA, Shoenfeld Y (2000) The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome. Molecular mimicry? J Rheumatol 27:12-4
  17. Bucciarelli S, Espinosa G, Asherson RA et al (2006) The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients. Ann Rheum Dis 65(1):81-6 CrossRef
  18. Stojanovich L (2006) Pulmonary Manifestations In Antiphospholipid Syndrome. Autoimmun Rev 5:344-48 CrossRef
  19. Wiedermann FJ, Mayr A, Schobersberger W et al (2000) Acute respiratory failure associated with catastrophic antiphospholipid syndrome. J Intern Med 247:723-30 CrossRef
  20. Burcoglu-O’ral A, Erkan D, Asherson RA (2002) Treatment of catastrophic antiphospholipid syndrome (CAPS) with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol 29:2006-011
  21. Vora SK, Asherson RA, Erkan D (2006) Catastrophic Antiphospholipid Syndrome. J Intensive Care Med 21:144-59 CrossRef
  22. Asherson RA, Cervera R, Klumb E, Stojanovich L et al (2008) Amputation of digits or limbs in patients with antiphospholipid syndrome. Semin Arthritis Rheum 38:124-31 CrossRef
  23. Asherson RA, Cervera R (2000) Catastrophic antiphospholipid syndrome. Curr Opin Hematol 7:325-29 CrossRef
  24. Cervera R, Gomez-Puerta JA, Espinosa G, Font J et al (2003) CAPS Registry: a review of 200 cases from the International Registry of patients with catastrophic antiphospholipid syndrome (CAPS) [abstract]. Ann Rheum Dis 62(suppl 1):88
  25. Shoenfeld Y, Zandman-Goddard G, Stojanovich L et al (2008) The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases-008. Isr Med Assoc J 10:8-2
  26. Asherson RA, Espinosa G, Cervera R et al (2002) Catastrophic antiphospholipid syndrome. Proposed guidelines for diagnosis and treatment. J Clin Rheumatol 8:157-65 CrossRef
  27. Shoenfeld Y, Ting G, Katz U, Sherer Y (2008) Autoantibody explosion in antiphospholipid syndrome. J Autoimmun 30:74-3 CrossRef
  28. Rand JH (2002) Molecular pathogenesis of antiphospholipid syndrome. Circ Res 90:29-7 CrossRef
  29. Hudson M, Herr AL, Rauch J et al (2003) The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol 30:2385-391
  30. Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D (1989) Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus. J Rheumatol 16:614-17
  31. de Groot PG, Horbach DA, Derksen RH (1996) Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus 5:488-93
  32. Asherson RA (2008) The primary, secondary, catastrophic, and seronegative variants of the antiphospholipid syndrome: a personal history long in the making. Semin Thromb Hemost 34(3):227-35 CrossRef
  33. Erkan D, Cervera R, Asherson RA (2003) Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum 48:3320-327 CrossRef
  34. Asherson RA, Espinosa G, Cervera R et al (2005) Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and hematological characteristics of 23 patients. Ann Rheum Dis 64:943-46 CrossRef
  35. Bucciareli I, Espinosa G, Cervera R et al (2006) Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54(8):2568-576 CrossRef
  
• 作者单位：Ljudmila Stojanovich (1)
  Dragomir Marisavljevic (1)
  Jozef Rovensky (2)
  Aleksandra Djokovich (1)
  Darina Kozáková (2)
  Nikola Milinic (1)
  
  1. University Medical Center “Bezanijska Kosa- Bezanijski put b.b., Novi Beograd, 11080, Belgrade, Serbia
  2. National Institute of Rheumatic Diseases, Piestany, Slovak Republic
  
• ISSN：1559-0267

文摘

Catastrophic antiphospholipid syndrome (CAPS, Asherson’s syndrome) is an unusual form of antiphospholipid syndrome (APS) characterized by multi-organ failure and high mortality. Fortunately, CAPS accounts for less than 1% of APS cases. Due to the rarity of the condition, an international registry of CAPS patients was created in 2000 supported by the European Forum on Antiphospholipid Antibodies held in Taormina, Italy at the Tenth International Congress on Antiphospholipid Antibodies. Clinical and laboratory features are the most important in the criteria for the diagnosis of this syndrome and can affect many organ systems. The majority of patients presented with multiple organ involvement at the time of CAPS. The combination of pulmonary, cardiac, and renal involvement was most commonly seen. The organ systems most commonly involved at the onset include the cardiopulmonary system, primarily characterized by dyspnea and respiratory failure, the central nervous system, and the renal system. Laboratory criteria for the classification of CAPS include the presence of antiphospholipid antibodies—LA and/or aCL and/or β2-GPI antibodies.